• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13D/A filed

    2/11/21 5:20:39 PM ET
    $CRMD
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $CRMD alert in real time by email
    SC 13D/A 1 p21-0684sc13da.htm CORMEDIX INC.
    SECURITIES AND EXCHANGE COMMISSION  
    Washington, D.C. 20549  
       
    SCHEDULE 13D/A
     
    Under the Securities Exchange Act of 1934
    (Amendment No. 1)
     

    CorMedix Inc.

    (Name of Issuer)
     

    Common Stock, par value $0.001 per share

    (Title of Class of Securities)
     

    21900C308

    (CUSIP Number)
     

    Elliott Investment Management, L.P.

    Phillips Point, East Tower

    777 South Flagler Drive, Suite 1000

    West Palm Beach, FL 33401

     

    with a copy to:

    Eleazer Klein, Esq.
    Marc Weingarten, Esq.

    Schulte Roth & Zabel LLP

    919 Third Avenue

    New York, New York 10022

    (212) 756-2000

    (Name, Address and Telephone Number of Person
    Authorized to Receive Notices and Communications)
     

    February 9, 2021

    (Date of Event Which Requires Filing of This Statement)
     

     

    If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of Rule 13d-1(e), Rule 13d-1(f) or Rule 13d-1(g), check the following box. ¨

     

    (Page 1 of 4 Pages)

    ______________________________

    * The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

     

    The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

    CUSIP No. 21900C308Schedule 13D/APage 2 of 4 Pages

     

    1

    NAME OF REPORTING PERSON

    Elliott Investment Management L.P.

    2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) ¨

    (b) ¨

    3 SEC USE ONLY
    4

    SOURCE OF FUNDS

    OO

    5 CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDING IS REQUIRED PURSUANT TO ITEMS 2(d) or 2(e) ¨
    6

    CITIZENSHIP OR PLACE OF ORGANIZATION

    Delaware

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON WITH:
    7

    SOLE VOTING POWER

    7,136,979 shares of Common Stock (including 391,953 shares of Common Stock issuable upon conversion of the Series E Preferred Stock and 5,560,137 shares of Common Stock issuable upon conversion of the Series G Preferred Stock)*

    8

    SHARED VOTING POWER

    -0-

    9

    SOLE DISPOSITIVE POWER

    7,136,979 shares of Common Stock (including 391,953 shares of Common Stock issuable upon conversion of the Series E Preferred Stock and 5,560,137 shares of Common Stock issuable upon conversion of the Series G Preferred Stock)*

    10

    SHARED DISPOSITIVE POWER

    -0-

    11

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH PERSON

    7,136,979 shares of Common Stock (including 391,953 shares of Common Stock issuable upon conversion of the Series E Preferred Stock and 5,560,137 shares of Common Stock issuable upon conversion of the Series G Preferred Stock)*

    12 CHECK IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES ¨
    13

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

    4.99% (See Item 6)*

    14

    TYPE OF REPORTING PERSON

    PN, IA

             

     

    * As more fully described in Item 6 of the original Schedule 13D filed on August 10, 2020, the shares of Common Stock issuable upon conversion of the Series E Preferred Stock and Series G Preferred Stock are subject to an Ownership Limitation (as defined in Item 6) and the percentage set forth in row (11) gives effect to the Ownership Limitation. However, rows (6), (8) and (9) show the number of shares of Common Stock that would be issuable upon the conversion in full of the reported Series E Preferred Stock and Series G Preferred Stock and do not give effect to the Ownership Limitation. Therefore, the actual number of shares of Common Stock beneficially owned by such Reporting Person, after giving effect to the Ownership Limitation, is less than the number of securities reported in rows (6), (8) and (9).

     

    CUSIP No. 21900C308Schedule 13D/APage 3 of 4 Pages

    The following constitutes Amendment No. 1 to the Schedule 13D filed by the undersigned ("Amendment No. 1"). This Amendment No. 1 amends the Schedule 13D as specifically set forth herein.

     

    Item 3. SOURCE AND AMOUNT OF FUNDS OR OTHER CONSIDERATION

     

    Item 3 is hereby amended and restated as follows:

     

    The aggregate purchase price of the shares of Common Stock reported herein is approximately $4,644,922.

     

    The Reporting Person may effect purchases of the shares of Common Stock through margin accounts maintained for the Elliott Funds with prime brokers, which extend margin credit as and when required to open or carry positions in their margin accounts, subject to applicable federal margin regulations, stock exchange rules and such firms' credit policies. Positions in the shares of Common Stock may be held in margin accounts and may be pledged as collateral security for the repayment of debit balances in such accounts. Since other securities may be held in such margin accounts, it may not be possible to determine the amounts, if any, of margin used to purchase the shares of Common Stock.

     

    Item 4. PURPOSE OF TRANSACTION

     

    Item 4 is hereby amended and supplemented by the addition of the following:
     
    The Reporting Person reduced the economic exposure of the Elliott Funds for portfolio management purposes. The Elliott Funds remain significant shareholders of the Issuer and own economic exposure to the Issuer equivalent to greater than 7 million shares of Common Stock through the Elliott Funds’ holdings of Common Stock and shares of Common Stock underlying the Series E Preferred Stock and Series G Preferred Stock as previously described in Item 6. The Reporting Person continues to have great confidence in the Issuer's leadership and operational trajectory.

     

    Item 5. INTEREST IN SECURITIES OF THE ISSUER

     

    Item 5 is hereby amended and restated as follows:
     
    (a) See rows (11) and (13) of the cover page to this Schedule 13D for the aggregate number of shares of Common Stock and percentage of the shares of Common Stock beneficially owned by the Reporting Person.  The aggregate percentage of Common Stock reported beneficially owned by the Reporting Person is based upon 32,132,492 shares of Common Stock outstanding as of November 4, 2020, as reported in the Issuer's Prospectus Supplement filed pursuant to Rule 424(b)(5) with the Securities and Exchange Commission on November 27, 2020.
     
    (b) See rows (7) through (10) of the cover page to this Schedule 13D for the number of shares of Common Stock as to which the Reporting Person has the sole or shared power to vote or direct the vote and sole or shared power to dispose or to direct the disposition.
     
    (c) The transactions in the shares of Common Stock effected on behalf of the Elliott Funds and/or their respective subsidiaries in the past sixty (60) days, which were all in the open market, are set forth on Schedule 1 attached hereto.
     
    (d) No persons other than the Elliott Funds and/or their respective subsidiaries and EIM have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the shares of Common Stock beneficially owned by EIM.
     
    (e) February 9, 2021.

     

    CUSIP No. 21900C308Schedule 13D/APage 4 of 4 Pages

    SIGNATURES

    After reasonable inquiry and to the best of its knowledge and belief, the undersigned certifies that the information set forth in this statement is true, complete and correct.

    DATE: February 11, 2021

     

    Elliott Investment Management L.P.    
         
    /s/ Elliot Greenberg    
    Name: Elliot Greenberg    
    Title: Vice President    

     

     

    SCHEDULE 1

     

    Transactions Effected in the Past 60 Days

     

    The following transactions in the Common Stock were effected on behalf of the Elliott Funds or their respective subsidiaries in the past sixty (60) days:

     

    Date Amount of Shs.
    Bought / (Sold)
    Approx. price ($)
    per Share
         
    02/11/2021 (56,474) 13.55
    02/10/2021 (145,873) 14.13
    02/09/2021 (171,138) 14.40
    02/05/2021 (200,000) 14.67

     

    Get the next $CRMD alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $CRMD

    DatePrice TargetRatingAnalyst
    3/7/2025$18.00Outperform
    Leerink Partners
    1/13/2025$15.00Buy
    D. Boral Capital
    8/26/2024$13.00Buy
    Rodman & Renshaw
    8/10/2023$6.00Outperform
    RBC Capital Mkts
    More analyst ratings

    $CRMD
    Leadership Updates

    Live Leadership Updates

    See more
    • CorMedix Inc. Announces Appointment of Chief Legal Officer

      BERKELEY HEIGHTS, N.J., Dec. 15, 2023 (GLOBE NEWSWIRE) -- CorMedix Inc. (NASDAQ:CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of life-threatening diseases and conditions, today announced the appointment of Beth Zelnick Kaufman, Esq. as EVP, Chief Legal Officer, and Corporate Secretary, effective December 12, 2023. The Company also announced that, upon mutual agreement with the Company, Dr. Phoebe Mounts will no longer serve as the Company's General Counsel, effective December 12, 2023, and will be separating from CorMedix effective December 31, 2023, to pursue other opportunities. Ms. Zelnick Kaufman has

      12/15/23 8:30:00 AM ET
      $CRMD
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • CorMedix Inc. Announces Partnership With The Leapfrog Group

      – CorMedix to advocate for patient safety and infection prevention as part of Leapfrog's Partners Advisory Committee BERKELEY HEIGHTS, N.J., Dec. 04, 2023 (GLOBE NEWSWIRE) -- CorMedix Inc. (NASDAQ:CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of life-threatening diseases and conditions, today announced an agreement with The Leapfrog Group, an independent national watchdog organization of employers and other purchasers focused on health care safety, whereby CorMedix Inc. will become a member of the Leapfrog Partners Advisory Committee. The Partners Advisory Committee is a platform for the crea

      12/4/23 8:30:00 AM ET
      $CRMD
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Cormedix Inc. Announces Appointment of Robert A. Stewart to Its Board of Directors

      BERKELEY HEIGHTS, N.J., April 17, 2023 (GLOBE NEWSWIRE) -- CorMedix Inc. (NASDAQ:CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of life-threatening conditions and diseases, today announced the appointment of Robert A. Stewart to the CorMedix Board of Directors. Following the appointment of Mr. Stewart, the Board will comprise 8 directors, 7 of which are independent. "We are pleased to welcome Rob Stewart to the CorMedix Board," said Joseph Todisco, Chief Executive Officer of CorMedix. "Rob's deep experience in global pharmaceutical management and broad professional network in the pharma space will be inval

      4/17/23 8:30:00 AM ET
      $CRMD
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CRMD
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by CorMedix Inc.

      SC 13G/A - CorMedix Inc. (0001410098) (Subject)

      11/14/24 4:34:05 PM ET
      $CRMD
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by CorMedix Inc. (Amendment)

      SC 13G/A - CorMedix Inc. (0001410098) (Subject)

      2/14/24 10:37:21 AM ET
      $CRMD
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by CorMedix Inc.

      SC 13G - CorMedix Inc. (0001410098) (Subject)

      2/13/24 5:02:29 PM ET
      $CRMD
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CRMD
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • CorMedix Inc. Reports First Quarter 2025 Financial Results and Provides Business Update

      ‒ Q1 2025 Net Revenue of $39.1mm; Adjusted EBITDA of $23.6mm ‒ Conference Call Scheduled for Today at 8:30 a.m. Eastern Time BERKELEY HEIGHTS, NJ., May 06, 2025 (GLOBE NEWSWIRE) -- CorMedix Inc. (NASDAQ:CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and conditions, today announced financial results for the first quarter ended March 31, 2025 and provided an update on its business. Recent Corporate Highlights: CorMedix announces net sales of $39.1 million for the first quarter of 2025, largely driven by successful implementation by its outpatient dialys

      5/6/25 7:30:00 AM ET
      $CRMD
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • CorMedix Inc. to Report First Quarter 2025 Financial Results and Provide a Corporate Update on May 6, 2025

      BERKELEY HEIGHTS, N.J., April 29, 2025 (GLOBE NEWSWIRE) -- CorMedix Inc. (NASDAQ:CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and conditions, today announced that it will report its financial results for the first quarter ended March 31, 2025, before the market opens on Tuesday, May 6, 2025, and will host a corporate update conference call at 8:30am Eastern Time. Tuesday, May 6th @ 8:30am ETDomestic:1-844-676-2922International:1-412-634-6840Conference ID:10198548Webcast:Webcast Link   About CorMedix CorMedix Inc. is a biopharmaceutical company focused on developing and commercializing therapeutic pr

      4/29/25 8:30:00 AM ET
      $CRMD
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Cormedix Inc. Announces Preliminary First Quarter 2025 Results and Raises H1 2025 Net Sales Guidance

      ‒ Q1 2025 Unaudited Net Revenue of $39.0 million ‒ ‒ Expected Q1 Adjusted EBITDA above $22.5 million ‒ ‒ Q1 2025 Cash and Cash Equivalents of Approximately $77.5 million ‒ BERKELEY HEIGHTS, N.J., April 08, 2025 (GLOBE NEWSWIRE) -- CorMedix Inc. (NASDAQ:CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and conditions, today announces its preliminary unaudited first quarter results and provides an update on its business. These include the following key updates: CorMedix announces preliminary, unaudited net revenue of $39.0 million for 1Q 2025, and expects 1Q 2025 adjusted EBITDA(1) to exceed $22

      4/8/25 7:30:00 AM ET
      $CRMD
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CRMD
    SEC Filings

    See more

    $CRMD
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    See more

    $CRMD
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 10-Q filed by CorMedix Inc.

      10-Q - CorMedix Inc. (0001410098) (Filer)

      5/6/25 8:32:06 AM ET
      $CRMD
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • CorMedix Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - CorMedix Inc. (0001410098) (Filer)

      5/6/25 7:45:34 AM ET
      $CRMD
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form DEFA14A filed by CorMedix Inc.

      DEFA14A - CorMedix Inc. (0001410098) (Filer)

      4/28/25 4:31:37 PM ET
      $CRMD
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • November 17, 2023 - FDA Roundup: November 17, 2023

      For Immediate Release: November 17, 2023 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency:  Today, to mark the 15th anniversary of the FDA foreign offices, the FDA published an interview with Susan Winckler, who was FDA chief of staff when the first office was opened in Beijing on November 19, 2008. Winckler is now CEO of the Reagan-Udall Foundation

      11/17/23 4:18:44 PM ET
      $BMY
      $CRMD
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • FDA Approval for DEFENCATH issued to CORMEDIX INC

      Submission status for CORMEDIX INC's drug DEFENCATH (ORIG-1) with active ingredient TAUROLIDINE AND HEPARIN SODIUM has changed to 'Approval' on 11/15/2023. Application Category: NDA, Application Number: 214520, Application Classification: Type 1 - New Molecular Entity and Type 4 - New Combination

      11/15/23 9:53:06 AM ET
      $CRMD
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Lefkowitz Steven W exercised 20,000 shares at a strike of $4.03, increasing direct ownership by 20% to 120,498 units (SEC Form 4)

      4 - CorMedix Inc. (0001410098) (Issuer)

      4/3/25 4:30:05 PM ET
      $CRMD
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chief Executive Officer Todisco Joseph exercised 59,170 shares at a strike of $3.38, increasing direct ownership by 13% to 530,721 units (SEC Form 4)

      4 - CorMedix Inc. (0001410098) (Issuer)

      4/2/25 7:00:03 AM ET
      $CRMD
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chief Executive Officer Todisco Joseph was granted 187,500 shares and covered exercise/tax liability with 23,977 shares, increasing direct ownership by 53% to 471,551 units (SEC Form 4)

      4 - CorMedix Inc. (0001410098) (Issuer)

      1/22/25 9:11:40 PM ET
      $CRMD
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CRMD
    Financials

    Live finance-specific insights

    See more
    • CorMedix Inc. Reports First Quarter 2025 Financial Results and Provides Business Update

      ‒ Q1 2025 Net Revenue of $39.1mm; Adjusted EBITDA of $23.6mm ‒ Conference Call Scheduled for Today at 8:30 a.m. Eastern Time BERKELEY HEIGHTS, NJ., May 06, 2025 (GLOBE NEWSWIRE) -- CorMedix Inc. (NASDAQ:CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and conditions, today announced financial results for the first quarter ended March 31, 2025 and provided an update on its business. Recent Corporate Highlights: CorMedix announces net sales of $39.1 million for the first quarter of 2025, largely driven by successful implementation by its outpatient dialys

      5/6/25 7:30:00 AM ET
      $CRMD
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • CorMedix Inc. to Report First Quarter 2025 Financial Results and Provide a Corporate Update on May 6, 2025

      BERKELEY HEIGHTS, N.J., April 29, 2025 (GLOBE NEWSWIRE) -- CorMedix Inc. (NASDAQ:CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and conditions, today announced that it will report its financial results for the first quarter ended March 31, 2025, before the market opens on Tuesday, May 6, 2025, and will host a corporate update conference call at 8:30am Eastern Time. Tuesday, May 6th @ 8:30am ETDomestic:1-844-676-2922International:1-412-634-6840Conference ID:10198548Webcast:Webcast Link   About CorMedix CorMedix Inc. is a biopharmaceutical company focused on developing and commercializing therapeutic pr

      4/29/25 8:30:00 AM ET
      $CRMD
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • CorMedix Inc. Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

      ‒ Q4 2024 Net Revenue of $31.2mm; 2024 Net Revenue of $43.5mm ‒ ‒ Q4 Net Income of $13.5mm and Adjusted EBITDA of $15.3mm ‒ ‒ Conference Call Scheduled for Today at 8:30 a.m. Eastern Time ‒ BERKELEY HEIGHTS, N.J., March 25, 2025 (GLOBE NEWSWIRE) -- CorMedix Inc. (NASDAQ:CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and conditions, today announced financial results for the fourth quarter and full year ended December 31, 2024 and provided an update on its business. Recent Corporate Highlights: CorMedix today reports its second full quarter of DefenCath sales since commencing outpatient launch in

      3/25/25 7:30:00 AM ET
      $CRMD
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CRMD
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Leerink Partners initiated coverage on Cormedix with a new price target

      Leerink Partners initiated coverage of Cormedix with a rating of Outperform and set a new price target of $18.00

      3/7/25 7:21:39 AM ET
      $CRMD
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • D. Boral Capital initiated coverage on Cormedix with a new price target

      D. Boral Capital initiated coverage of Cormedix with a rating of Buy and set a new price target of $15.00

      1/13/25 8:29:07 AM ET
      $CRMD
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Rodman & Renshaw initiated coverage on Cormedix with a new price target

      Rodman & Renshaw initiated coverage of Cormedix with a rating of Buy and set a new price target of $13.00

      8/26/24 7:31:35 AM ET
      $CRMD
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CRMD
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • EVP, Chief Commercial Officer Mistry Erin bought $14,985 worth of shares (1,500 units at $9.99), increasing direct ownership by 3% to 52,011 units (SEC Form 4)

      4 - CorMedix Inc. (0001410098) (Issuer)

      12/13/24 4:15:22 PM ET
      $CRMD
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Todisco Joseph bought $50,718 worth of shares (13,561 units at $3.74), increasing direct ownership by 4% to 352,839 units (SEC Form 4)

      4 - CorMedix Inc. (0001410098) (Issuer)

      3/14/24 8:45:21 AM ET
      $CRMD
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Dunton Alan W bought $20,250 worth of shares (6,000 units at $3.38), increasing direct ownership by 65% to 15,250 units (SEC Form 4)

      4 - CorMedix Inc. (0001410098) (Issuer)

      12/18/23 4:47:41 PM ET
      $CRMD
      Biotechnology: Pharmaceutical Preparations
      Health Care